Pilaralisib

CAS: 934526-89-3

Ref. TM-T2365

Produktinformation

• Name: Pilaralisib
• Synonyme: SAR245408, XL-147, 2-Amino-N-[3-[N-[3-[(2-chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide, 2-Amino-N-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide, 2-Amino-N-[3-[[[3-[(2-chloro-5-methoxyphenyl)amino]-2-quinoxalinyl]amino]sulfonyl]phenyl]-2-methylpropanamide, 3-Cyano-5-fluorobenzaldehyde, 3-Fluoro-5-formylbenzonitrile, Benzonitrile, 3-fluoro-5-formyl-, N-(3-(benzo[c][1,2,5]thiadiazol-5-ylamino)quinoxalin-2-yl)-4-methylbenzenesulfonamide, N-[3-(2,1,3-Benzothiadiazol-5-ylamino)-2-quinoxalinyl]-4-methylbenzenesulfonamide, Propanamide, 2-amino-N-[3-[[[3-[(2-chloro-5-methoxyphenyl)amino]-2-quinoxalinyl]amino]sulfonyl]phenyl]-2-methyl-, SC, Sar 245408, Sar245408, Xl-147, Xl147
• CAS: 934526-89-3

Beschreibung

Pilaralisib (XL-147) is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.

• Marke: Targetmol

Chemische Eigenschaften

• Molekulargewicht: 541.02
• Formel: C₂₅H₂₅ClN₆O₄S
• Reinheit: 99.61%
• Farbe/Form: Solid